Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
Milanova Tsveta, the Chief Commercial Officer of Agios Pharmaceuticals Inc. (NASDAQ:AGIO), recently sold shares of the company’s common stock. According to a recent SEC filing, Tsveta sold 1,681 shares on March 3 at a price of $35.54 per share, totaling approximately $59,742. This transaction was executed to cover tax obligations related to the vesting of restricted stock units. The sale comes as the stock, currently trading at $33.39, has seen significant price decline over the past three months. According to InvestingPro analysis, AGIO appears undervalued, with analyst price targets ranging from $43 to $74.
In addition to the sale, Tsveta acquired 5,667 shares of common stock through the vesting of restricted stock units on March 1. The officer also received 12,000 restricted stock units and 43,500 stock options, which were granted on the same date. These grants will vest over a period of time, according to the terms outlined in the agreement. The $1.92 billion market cap company maintains strong liquidity with a current ratio of 11.9. For deeper insights into insider trading patterns and comprehensive financial analysis, explore InvestingPro, which offers exclusive research reports and real-time data on over 1,400 US stocks.
In other recent news, Agios Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of -$1.44, compared to the forecast of -$1.68. The company also exceeded revenue projections, reporting $10.7 million against the expected $9.32 million, marking a 51% year-over-year increase in net Pyrakind revenue. Agios ended the quarter with a strong cash position of $1.5 billion, which is expected to support future growth and potential product launches. Additionally, H.C. Wainwright initiated coverage on Agios Pharmaceuticals with a Buy rating and a price target of $58. The firm expressed optimism about Agios’s lead asset, mitapivat, which has FDA approval for treating adult PK deficiency and potential for label expansion into thalassemia and sickle cell disease by 2026. The analyst from H.C. Wainwright noted that mitapivat’s established recognition among hematologists could lead to a successful commercial launch in thalassemia by September 2025. These developments reflect Agios Pharmaceuticals’ strong performance and strategic positioning in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.